CD274 and ovarian carcinoma: Immunotherapy strategies that have demonstrated success in other gynecological malignancies, such as checkpoint inhibition (e.g., PD-L1 blockade) [102], have displayed underwhelming results in ovarian cancer treatment [103,104].